| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/10/2004 | WO2004027372A3 Method for diagnosing rhabdomyosarcoma and pharmaceutical compositions for the treatment and/or prevention of rhabdomyosarcoma |
| 06/10/2004 | WO2004019891A3 Methods and compostions for immune tolerance |
| 06/10/2004 | WO2004017810A3 Tumor specific oligosaccharide epitopes and use thereof |
| 06/10/2004 | WO2004016763A3 Treatment of holocrine gland dysfunction with clostridia neurotoxins |
| 06/10/2004 | WO2004011484A9 Parathyroid hormone receptor activation and hematopoietic progenitor cell expansion |
| 06/10/2004 | WO2004004698A3 Proteins binding to cross-beta structure comprising amyloid and methods for detection and modulation of the cross-beta structure, its formation and its associated toxicity |
| 06/10/2004 | WO2004004633A3 Use of tnfalpha antibodies and another drug |
| 06/10/2004 | WO2004003145A3 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 06/10/2004 | WO2004003144A3 Antibodies that specifically bind to reg iv |
| 06/10/2004 | WO2004001425A3 Mhc class ii haplotype specific immunodominancy of peptides derived from rsv fusion (f) and attachement (g) proteins |
| 06/10/2004 | WO2003104436A3 Cancer-linked gene as target for chemotherapy |
| 06/10/2004 | WO2003089571A3 Ehrlichia canis genes and vaccines |
| 06/10/2004 | WO2003087323A3 Biologic modulations with nanoparticles |
| 06/10/2004 | WO2003084472A3 Recombinant p. falciparum merozoite protein-142 vaccine |
| 06/10/2004 | WO2003083039A8 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 06/10/2004 | WO2003079995A3 Neisseria mutants, lipooligosaccharides and immunogenic compositions |
| 06/10/2004 | WO2003077841A9 Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
| 06/10/2004 | WO2003061558A9 Glycoconjugate vaccines for use in immune-compromised populations |
| 06/10/2004 | WO2003040170A9 Antibodies to cd40 |
| 06/10/2004 | WO2003037258A3 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 06/10/2004 | WO2003026689A8 Autologous growth factor cocktail composition, method of production and use |
| 06/10/2004 | WO2003013603A8 Modulators of p-selectin glycoprotein ligand 1 |
| 06/10/2004 | WO2002090502A3 Highly conserved proteins from gram-positive bacteria |
| 06/10/2004 | US20040110941 by cloning, amplifying and expressing DNA sequences using polymerase chain reaction; for therapy, diagnosis or catalysis; solid phase synthesis |
| 06/10/2004 | US20040110935 Universal carrier for targeting molecules to Gb3 receptor expressing cells |
| 06/10/2004 | US20040110931 Prion and viral clearance process |
| 06/10/2004 | US20040110927 Expression vector coding secretory peptide antisense sequences for gene therapeutic treatment of tumors; antitumor agents |
| 06/10/2004 | US20040110919 Comprises toxic jellyfish protein for use as pesticide |
| 06/10/2004 | US20040110846 Perylenequinones for use with immunotherapy agents |
| 06/10/2004 | US20040110839 Compounds and compositions for delivering active agents |
| 06/10/2004 | US20040110774 HIV infection, AIDS, and adenosine deaminase deficiency-dependent severe immunodeficiency disease (ADA SCID); antagonists are antibodies |
| 06/10/2004 | US20040110755 for cytokine-mediated diseases such as Crohn's disease; mixture of an immunosuppressant, NSAIDs, angiogenesis inhibitors, steroids, retinoids, or cellular adhesion molecule inhibitor and specific urea- and morpholine-containing compounds |
| 06/10/2004 | US20040110735 Methods of activating receptor using amphiphilic drug-oligomer conjugates |
| 06/10/2004 | US20040110715 Differs from nucleotide sequence of wild-type IFN alpha -17 gene, in that it comprises one or several SNPs (Single Nucleotide Polymorphism[s]); anticarcinogenic and antiproliferative agents; side effect reduction |
| 06/10/2004 | US20040110712 Methods for treating patients and identifying therapeutics |
| 06/10/2004 | US20040110710 Methods of reducing ischemic injury |
| 06/10/2004 | US20040110706 Nucleic acid with point mutations, deletions, insertions and/or rearrangements ; hyperthermia, myasthenia, ataxia, neuropathic and inflammatory pain; Alzheimer*s, Parkinson's disease; schizophrenia, hyperekplexia, myotonias and arrhythmia |
| 06/10/2004 | US20040110695 Phospholipid vesicle having exogenous antigen orpolynucleic acid coding for antigen; adapted to be phagocytosed by antigen presenting cells |
| 06/10/2004 | US20040110674 Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer |
| 06/10/2004 | US20040110668 Nucleic acid sequences differentially expressed in cancer tissue |
| 06/10/2004 | US20040110283 Induction of tumor and viral immunity using antigen presenting cell co-culture products and fusion products |
| 06/10/2004 | US20040110269 Protection against mycobacterial infections |
| 06/10/2004 | US20040110268 Attenuated Pasteurellaceae virulence genes are identified and used to screen bactericides and produce vaccines which prevent infection |
| 06/10/2004 | US20040110261 Campylobacter nucleotide sequences coding transferase which modifies lipopolysaccharide for use in identifying agonist to infection; bactericides |
| 06/10/2004 | US20040110219 Detecting amount of nucleic acid encoding UKW polypeptide through hybridization and comparing with a predetermined standard value |
| 06/10/2004 | US20040110181 Novel streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof |
| 06/10/2004 | US20040110168 Diagnostics and therapeutics for osteoporosis |
| 06/10/2004 | US20040110165 Viral chemokine-antigen fusion proteins |
| 06/10/2004 | US20040109887 Immunogenic proteoliposomes, and uses thereof |
| 06/10/2004 | US20040109879 Method of Treating Herpes Virus Infections |
| 06/10/2004 | US20040109877 Rna viruses; attenuation influenza virus |
| 06/10/2004 | US20040109875 Pro-apoptotic bacterial vaccines to enhance cellular immune responses |
| 06/10/2004 | US20040109874 Generation immunology response on surface of mucous membrane; transdermal supplying; nucleic acid coding antigen |
| 06/10/2004 | US20040109873 Genetic engineering equine herpes virus; genes coding protein |
| 06/10/2004 | US20040109872 Porifera-based therapeutic compositions for treating and preventing skin diseases |
| 06/10/2004 | US20040109871 Gene, immunogen transfer ; induction mucous membrane immunity; polynucleotide sequences ; bactericides, viricides, fungicides, parasirtici des, anticancer agents |
| 06/10/2004 | US20040109869 Transcutaneous immunostimulation |
| 06/10/2004 | US20040109868 Pim kinase-related methods |
| 06/10/2004 | US20040109866 Immonotherapy complex containing antigen, antibodies, epitopes; binding to receptors |
| 06/10/2004 | US20040109859 Method for the treatment of multiple sclerosis |
| 06/10/2004 | US20040109858 Conformation-specific anti-von Willebrand factor antibodies |
| 06/10/2004 | US20040109857 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| 06/10/2004 | US20040109853 Biological active coating components, coatings, and coated surfaces |
| 06/10/2004 | US20040109851 Use of immature dendritic cells to silence antigen specific cd8cell function |
| 06/10/2004 | US20040109847 Treatment and prophylaxis with 4-1BB-binding agents |
| 06/10/2004 | US20040109846 Restoring cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| 06/10/2004 | US20040109844 Methods of treating age-related defects and diseases |
| 06/10/2004 | CA2518906A1 Method of obtaining cochlear structures, vaccine compositions, adjuvants and intermediates thereof |
| 06/10/2004 | CA2507551A1 An allergen dosage form |
| 06/10/2004 | CA2507215A1 Methods for treating cancer using porimin as a target |
| 06/10/2004 | CA2507018A1 Materials and methods for preventing and treating microbe-mediated epithelial disorders |
| 06/10/2004 | CA2507009A1 Multiple variants of meningococcal protein nmb1870 |
| 06/10/2004 | CA2506985A1 Preparation of polyphosphazene microspheres |
| 06/10/2004 | CA2506984A1 Polyphosphazene immunocstimulants |
| 06/10/2004 | CA2506820A1 A hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 06/10/2004 | CA2506666A1 Nact as a target for lifespan expansion and weight reduction |
| 06/10/2004 | CA2506526A1 Broad spectrum anti-viral therapeutics and prophylaxis |
| 06/10/2004 | CA2504561A1 Composition and method for treating lupus nephritis |
| 06/10/2004 | CA2504144A1 Compositions and methods for the diagnosis of immune related diseases using pro7 |
| 06/09/2004 | EP1426764A1 Method of diagnosing or monitoring saccharometabolic error |
| 06/09/2004 | EP1426044A1 Use of esters of L-carnitine or alkanoyl L-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds |
| 06/09/2004 | EP1425580A2 Lymphatic endothelial cells materials and methods |
| 06/09/2004 | EP1425423A2 Transcutaneous immunization against papillomavirus with papillomavirus virus-like particles |
| 06/09/2004 | EP1425396A2 Dna encoding the major allergen of plantago lanceolata pollen, pla 11 |
| 06/09/2004 | EP1425391A1 Therapeutic vaccination method, mutated peptides of hiv reverse transcriptase and their use for vaccination and diagnostic purposes |
| 06/09/2004 | EP1425389A2 Human antibodies specific for interleukin 15 (il-15) |
| 06/09/2004 | EP1425380A2 Retrovirus isolated from mantle histiocytes in mantle cell lymphoma |
| 06/09/2004 | EP1425305A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses |
| 06/09/2004 | EP1425301A2 Therapeutic vaccine peptide complex for preventing and treating disorders in mammals |
| 06/09/2004 | EP1425300A2 PHENOTYPE-DETERMINING VIRULENCE GENES OF i PSEUDOMONAS AERUGINOSA /i FOR COLONIZATION AND PERSISTENCE IN HUMAN BEINGS, ANIMALS AND PLANTS, USES OF SAID GENE AND ASSOCIATED PROTEINS |
| 06/09/2004 | EP1425299A2 Peptides derived from the superantigen (sag) env protein of herv-k18 and their use in obtaining sag-inhibitory antibodies and in vaccination |
| 06/09/2004 | EP1425298A2 Subunit respiratory syncytial virus vaccine preparation |
| 06/09/2004 | EP1425295A1 Modified peptides and their use for the treatment of autoimmune diseases |
| 06/09/2004 | EP1425042A1 Complement pathway inhibitors binding to c5 and c5a without preventing the formation of c5b |
| 06/09/2004 | EP1425041A2 Methods for sterilizing preparations of monoclonal immunoglobulins |
| 06/09/2004 | EP1425040A2 In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
| 06/09/2004 | EP1425039A2 Human papilloma virus immunoreative peptides |
| 06/09/2004 | EP1425038A1 Attenuated bacteria useful in vaccines |
| 06/09/2004 | EP1425037A2 Bacterial vaccine |
| 06/09/2004 | EP1425036A2 Virus coat protein/receptor chimeras and methods of use |